• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
HIF-PHIs for Anemia Management in CKD: Potential and Uncertainty ASCEND.用于慢性肾脏病贫血管理的低氧诱导因子脯氨酰羟化酶抑制剂：潜力与不确定性——ASCEND研究
Clin J Am Soc Nephrol. 2022 Aug;17(8):1255-1258. doi: 10.2215/CJN.02440222. Epub 2022 Jul 5.
2
Hypoxia-inducible factor-prolyl hydroxylase inhibitors for renal anemia in chronic kidney disease: Advantages and disadvantages.缺氧诱导因子脯氨酰羟化酶抑制剂治疗慢性肾脏病肾性贫血：优缺点。
Eur J Pharmacol. 2021 Dec 5;912:174583. doi: 10.1016/j.ejphar.2021.174583. Epub 2021 Oct 19.
3
Anemia Management in the Cancer Patient With CKD and End-Stage Kidney Disease.癌症合并慢性肾脏病和终末期肾病患者的贫血管理。
Adv Chronic Kidney Dis. 2022 Mar;29(2):180-187.e1. doi: 10.1053/j.ackd.2022.03.005.
4
Cardiac and Kidney Adverse Effects of HIF Prolyl-Hydroxylase Inhibitors for Anemia in Patients With CKD Not Receiving Dialysis: A Systematic Review and Meta-analysis.未透析慢性肾脏病患者贫血的低氧诱导因子脯氨酰羟化酶抑制剂的心脏和肾脏不良作用：系统评价和荟萃分析。
Am J Kidney Dis. 2023 Apr;81(4):434-445.e1. doi: 10.1053/j.ajkd.2022.09.014. Epub 2022 Nov 15.
5
Methoxy Polyethylene Glycol-Epoetin Beta as a Novel Erythropoiesis Stimulating Agent with Possible Nephroprotective and Cardiovascular Protective Effects in Non-Dialysis Chronic Kidney Disease Patients.甲氧基聚乙二醇-促红细胞生成素β作为一种新型促红细胞生成刺激剂，对非透析慢性肾脏病患者可能具有肾脏保护和心血管保护作用。
Curr Pharm Biotechnol. 2017;18(4):303-308. doi: 10.2174/1389201018666170127104801.
6
Daprodustat for the Treatment of Anemia in Patients Undergoing Dialysis.达普司他用于治疗透析患者的贫血
N Engl J Med. 2021 Dec 16;385(25):2325-2335. doi: 10.1056/NEJMoa2113379. Epub 2021 Nov 5.
7
Effects of hypoxia-inducible factor-prolyl hydroxylase inhibitors . erythropoiesis-stimulating agents on iron metabolism in non-dialysis-dependent anemic patients with CKD: A network meta-analysis.低氧诱导因子脯氨酰羟化酶抑制剂和促红细胞生成刺激剂对非透析依赖性 CKD 贫血患者铁代谢的影响：网状 Meta 分析。
Front Endocrinol (Lausanne). 2023 Mar 16;14:1131516. doi: 10.3389/fendo.2023.1131516. eCollection 2023.
8
Cardiovascular safety of current and emerging drugs to treat anaemia in chronic kidney disease: a safety review.当前和新兴药物治疗慢性肾脏病贫血的心血管安全性：安全性评价。
Expert Opin Drug Saf. 2023 Jul-Dec;22(12):1179-1191. doi: 10.1080/14740338.2023.2285889. Epub 2023 Dec 18.
9
The Safety of Erythropoiesis-Stimulating Agents for the Treatment of Anemia Resulting from Chronic Kidney Disease.促红细胞生成素治疗慢性肾脏病所致贫血的安全性
Clin Drug Investig. 2016 Jun;36(6):421-31. doi: 10.1007/s40261-016-0378-y.
10
Managing Anemia across the Stages of Kidney Disease in Those Hyporesponsive to Erythropoiesis-Stimulating Agents.管理对红细胞生成刺激剂低反应性的慢性肾脏病各期患者的贫血
Am J Nephrol. 2021;52(6):450-466. doi: 10.1159/000516901. Epub 2021 Jul 19.

引用本文的文献

1
Roxadustat for CKD-related anemia: a unified solution for non-dialysis, dialysis, and post-transplant patients.罗沙司他用于治疗慢性肾脏病相关贫血：为非透析、透析及移植后患者提供统一解决方案。
Int Urol Nephrol. 2025 Jul;57(7):2337-2338. doi: 10.1007/s11255-025-04385-6. Epub 2025 Jan 25.
2
Desidustat: a novel PHD inhibitor for the treatment of CKD-induced anemia.地西司他：一种用于治疗慢性肾脏病所致贫血的新型脯氨酰羟化酶抑制剂。
Front Nephrol. 2024 Oct 22;4:1459425. doi: 10.3389/fneph.2024.1459425. eCollection 2024.
3
Effect of roxadustat on iron metabolism in patients with peritoneal dialysis: a real-world 24-week study.罗沙司他对腹膜透析患者铁代谢的影响：一项真实世界的 24 周研究。
Eur J Med Res. 2023 Nov 7;28(1):489. doi: 10.1186/s40001-023-01465-0.
4
A Rationally Designed Complex Replenishes the Transferrin Iron Pool Directly and with High Specificity.一种理性设计的复合物可直接且高特异性地补充转铁蛋白铁池。
J Am Chem Soc. 2023 Mar 29;145(12):6871-6879. doi: 10.1021/jacs.3c00123. Epub 2023 Mar 15.

HIF-PHIs for Anemia Management in CKD: Potential and Uncertainty ASCEND.

作者信息

McCallum Wendy, Weiner Daniel E

机构信息

William B. Schwartz MD Division of Nephrology, Tufts Medical Center, Boston, Massachusetts.

出版信息

Clin J Am Soc Nephrol. 2022 Aug;17(8):1255-1258. doi: 10.2215/CJN.02440222. Epub 2022 Jul 5.

DOI:10.2215/CJN.02440222
PMID:35790236
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9435979/
Abstract
摘要